MOTS-C — Your Mitochondria
Made It. Now It's a Prescription.

Peptide origin

Mitochondrial genome — encoded in the 12S rRNA region (not nuclear DNA)

Length

16 amino acids

Discovered

2015 — USC Leonard Davis School of Gerontology

Primary mechanism

AMPK activation → mitochondrial biogenesis, insulin sensitization, metabolic flexibility

Primary tissue of production

Skeletal muscle — also detected in circulation and other metabolically active tissues

Levels decline with

Age, obesity, insulin resistance, mitochondrial dysfunction

AMPK Activation — The Master Metabolic Switch

AMP-activated protein kinase (AMPK) is the cell's primary energy sensor — it detects the ratio of AMP to ATP and activates when energy is low or demand is high. AMPK activation triggers a cascade of metabolic adaptations: increased glucose uptake, enhanced fatty acid oxidation, inhibition of anabolic processes that consume energy unnecessarily, and — critically — stimulation of mitochondrial biogenesis. MOTS-C directly activates AMPK, mimicking the metabolic state of exercise and caloric restriction at the cellular level. This is why MOTS-C and exercise have overlapping metabolic effects — they converge on the same sensing pathway.

Mitochondrial Biogenesis

Mitochondrial biogenesis — the production of new mitochondria — is one of the most important adaptations to metabolic demand. More mitochondria means greater capacity for oxidative phosphorylation, higher aerobic energy production, and better fat oxidation. AMPK activation by MOTS-C upregulates PGC-1alpha, the master regulator of mitochondrial biogenesis, driving the production of new mitochondria in muscle and other metabolically active tissues. Over time this translates to measurable improvements in aerobic capacity, fat oxidation, and cellular energy efficiency.

Insulin Sensitivity and Glucose Metabolism

MOTS-C improves insulin sensitivity through multiple interconnected mechanisms: AMPK-driven GLUT4 translocation (increased glucose transporter expression at the cell membrane), reduced lipid accumulation in muscle tissue (a primary driver of insulin resistance), and improved mitochondrial fatty acid oxidation that prevents the lipotoxic byproducts that interfere with insulin signaling. In animal models, MOTS-C administration reverses diet-induced insulin resistance — the effect is mechanistically coherent with its role as a mitochondrial energy signal.

Metabolic Flexibility

Metabolic flexibility — the ability to efficiently switch between glucose and fat as fuel sources depending on availability and demand — is one of the defining characteristics of metabolic health and one of the first things lost in metabolic disease. MOTS-C improves metabolic flexibility by enhancing the mitochondrial machinery for fat oxidation and by normalizing the signaling environment in which fuel selection occurs. Patients with poor metabolic flexibility often experience energy crashes, carbohydrate dependency, and difficulty losing fat even in caloric deficit.

Exercise Mimicry and Physical Performance

MOTS-C is sometimes grouped with compounds described as exercise mimetics — not because it replaces exercise, but because its AMPK-activating mechanism produces adaptations that parallel those of aerobic training. In preclinical studies, MOTS-C increased running endurance, improved body composition, and enhanced metabolic parameters in ways that closely mirrored the effects of regular aerobic exercise. For patients whose exercise capacity is limited by illness, injury, or age-related decline, MOTS-C targets the same cellular pathways that exercise activates.

More mitochondria, better-functioning mitochondria, and improved fuel utilization combine to produce a meaningful increase in cellular energy output. Patients describe this not as a stimulant effect but as more sustained, consistent energy — the kind that comes from metabolic machinery working properly.

MOTS-C's AMPK activation directly promotes fat oxidation and improves the hormonal and metabolic environment for body recomposition. Visceral fat reduction is a particular area of relevance. The effect accumulates over weeks to months and is amplified when paired with appropriate diet and exercise.

For patients with insulin resistance, pre-diabetes, or metabolic syndrome, MOTS-C addresses the mitochondrial dysfunction that underlies the condition rather than managing its downstream consequences. Improved insulin sensitivity has downstream effects on energy, fat storage, inflammation, and long-term cardiometabolic risk.

Mitochondrial biogenesis driven by MOTS-C increases oxidative capacity — the cellular infrastructure for sustained aerobic effort. Athletes and active patients report improvements in endurance, reduced perceived exertion, and faster recovery between training sessions.

MOTS-C levels decline with age in a pattern that mirrors the metabolic deterioration of aging — reduced energy efficiency, increased insulin resistance, declining physical capacity, and accumulating fat mass. Restoring MOTS-C signaling addresses these aging-related metabolic changes at their mitochondrial origin point.

Metabolically Compromised Patients — Insulin Resistance, Pre-Diabetes

Patients with insulin resistance, metabolic syndrome, or pre-diabetes are dealing with impaired mitochondrial function as a root cause. MOTS-C addresses this directly — restoring the AMPK signaling and mitochondrial metabolic capacity that insulin-resistant cells have lost. It is not a substitute for lifestyle intervention but is a meaningful addition to a metabolic rehabilitation protocol.

Patients Struggling with Fat Loss Despite Diet and Exercise

When caloric deficit and exercise are not producing expected fat loss results, impaired mitochondrial fat oxidation and poor metabolic flexibility are frequently contributing factors. MOTS-C improves the cellular machinery for fat burning — the mitochondrial capacity that diet and exercise alone cannot always restore quickly enough.

Athletes Seeking Performance and Recovery Gains

MOTS-C's mitochondrial biogenesis effects directly increase oxidative capacity — more mitochondria, better aerobic energy production, faster recovery. Athletes in endurance sports or high-volume training blocks who want to amplify the adaptations from their training are a natural fit.

Patients Using Weight Loss Peptides

MOTS-C is available as part of the AOD-9604/MOTS-C/Tesamorelin/Ipamorelin four-compound weight loss stack. Patients already on GLP-1 protocols who want to address the mitochondrial efficiency component of their metabolic profile can add standalone MOTS-C to their existing protocol.

Longevity-Oriented Patients

Patients engaged with anti-aging and longevity protocols who want to address metabolic aging at the mitochondrial level. MOTS-C complements telomere-focused compounds (Epithalon), cellular energy compounds (NAD+), and other mitochondrial compounds by targeting the AMPK-driven biogenesis and metabolic flexibility arm of mitochondrial longevity.

Available Concentrations

MOTS-C is available in two concentrations: 2mg/mL (5mL vial) and 10mg/mL (5mL vial). The 2mg/mL format supports lower-dose protocols; the 10mg/mL format supports higher-dose protocols or patients who prefer a smaller injection volume per dose.

Typical Dose Range

5–10mg subcutaneously, 2–5 times per week depending on clinical goals and individual response. Metabolic optimization and longevity protocols often use lower-frequency dosing (2–3x/week); performance and active fat loss protocols may use higher frequency. Your provider will establish the appropriate schedule.

Timing

MOTS-C is commonly administered pre-workout to leverage its AMPK-activating and fuel utilization effects during training. Morning administration on non-training days maintains the metabolic signaling environment consistently. Your provider may specify a different timing based on your goals.

Cycle Structure

MOTS-C can be used in continuous protocols of 8–12 weeks or in defined cycles with structured rest periods. The metabolic benefits — improved insulin sensitivity, body composition changes, increased aerobic capacity — accumulate over weeks and continue to develop after dosing windows close as mitochondrial biogenesis takes time to translate into measurable physiological change.

Stacking Considerations

MOTS-C pairs naturally with NAD+ (complementary mitochondrial energy optimization — NAD+ supports electron transport chain function; MOTS-C drives biogenesis of the mitochondria themselves), and with AOD-9604 or Tesamorelin for comprehensive metabolic and fat reduction protocols. The AOD-9604/MOTS-C/Tesamorelin/Ipamorelin four-compound blend is available as a single formulation. Your provider will advise on appropriate combinations.

MOTS-C 2mg/mL — 5mL Injectable

Entry-concentration format. Supports lower-dose protocols (5–10mg per dose). Subcutaneous injection, pre-workout or morning administration.

$191.67

Subcutaneous Injection

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs

MOTS-C 10mg/mL — 5mL Injectable

High-concentration format. Supports higher-dose protocols with a smaller injection volume per dose.

$275.00

Subcutaneous Injection

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs

AOD-9604 / MOTS-C / Tesamorelin / Ipamorelin Blend — 5mL

Four-compound metabolic stack: AOD-9604 + MOTS-C + Tesamorelin + Ipamorelin. Lipolysis, mitochondrial biogenesis, visceral fat reduction, and GH amplification in a single injection.

$266.67

Subcutaneous Injection

• Async telehealth provider consultation
• Prescription fulfillment through Optimal Balance Pharmacy
• FedEx Standard Overnight shipping
• Syringes and alcohol swabs